# A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma

> **NCT07252375** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fujian Cancer Hospital** · enrollment: 35 (estimated)

## Conditions studied

- Nasopharyngeal Carcinoma (NPC)
- CTIT-Chemotherapy Induced Thrombocytopenia

## Interventions

- **DRUG:** herombopag olamine tablets

## Key facts

- **NCT ID:** NCT07252375
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-30
- **Primary completion:** 2028-05-30
- **Final completion:** 2028-11-30
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07252375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07252375, "A Clinical Study of Hetrombopag for Prevention of Thrombocytopenia Induced by Gemcitabine Plus Cisplatin in the Treatment of Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07252375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*